天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (10): 1020-1024.doi: 10.11958/20200611

• 综述 • 上一篇    

嵌合抗原受体修饰T细胞治疗前列腺癌的研究进展

尤祥云1，2，向振东2，易成2，张满2，喻俊峰2△   

  1. 1三峡大学人民医院泌尿外科（邮编443000）；2湖北省宜昌市第一人民医院泌尿外科
  • 收稿日期:2020-03-21 修回日期:2020-07-30 出版日期:2020-10-15 发布日期:2020-10-30
  • 通讯作者: 尤祥云 E-mail:964032950@qq.com
  • 基金资助:
    宜昌市财政科技专项基金资助项目（A20-2-021）

Advances in the treatment of prostate cancer by chimeric antigen receptor modified T cells

YOU Xiang-yun1, 2, XIANG Zhen-dong2, YI Cheng2, ZHANG Man2, YU Jun-feng2△   

  1. 1 Department of Urology, the People’s Hospital of China Three Gorges University, Yichang 443000, China; 2 Department of Urology, the First People’s Hospital of Yichang
  • Received:2020-03-21 Revised:2020-07-30 Published:2020-10-15 Online:2020-10-30
  • Contact: xiangyun you E-mail:964032950@qq.com

PDF (PC)

5212

摘要：

摘要：嵌合抗原受体修饰T细胞（CAR-T）是近年来免疫治疗的热点，在血液系统疾病的治疗中取得了显著的临床疗效。目前，CAR-T在前列腺癌（PCa）治疗的研究中也取得了较大进展，其中以前列腺特异性膜抗原（PSMA）和前列腺干细胞抗原（PSCA）为靶点的CAR-T治疗进展较快，其可显著抑制肿瘤细胞生长，一定程度地延缓疾病进展。本文综述了前列腺肿瘤相关抗原（TAA）在前列腺癌CAR-T治疗中的最新研究进展，并对CAR-T在前列腺癌治疗中的挑战予以简要探讨，以期为临床提供参考。

关键词: 前列腺肿瘤, 免疫治疗, 嵌合抗原受体修饰T细胞, 前列腺特异性膜抗原, 前列腺干细胞抗原

Abstract:

Abstract：The research of chimeric antigen receptor modification T cells (CAR-T) is a hotspot in immunotherapy in recent years, which has achieved remarkable clinical efficacy in the treatment of hematological diseases. At present, CAR-T has also made great progress in the treatment of prostate cancer (PCa). CAR-T therapy targeting prostate-specific membrane antigen (PSMA) and prostate-stem cell antigen (PSCA) has made rapid progresses, which can significantly inhibit tumor cell growth and delay disease progression in a certain extent. This article reviewed the recent clinical research progress of prostate cancer associated antigen (TAA) in the treatment of prostate cancer with CAR-T, and briefly discussed the challenges of CAR-T in the treatment of prostate cancer for better clinical application.

Key words: prostatic neoplasms, immunotherapy, chimeric antigen receptor modified T cell, prostate-specific membrane antigen, prostate-stem cell antigen